GlaxoSmithKline submits Cervarix application

Share this article:
The pursuit to become the top-selling cervical cancer vaccine intensified last week as GlaxoSmithKline submitted its Biologics License Application (BLA) for Cervarix with the FDA. Cervarix is being developed to prevent strains of the sexually transmitted human papillomavirus (HPV), which can cause cervical cancer. The vaccine could reach the market by the end of 2007, if the FDA grants it “fast-track” status and then approves it, GlaxoSmithKline CEO Jean-Pierre Garnier said in a recent interview with CNNMoney.com. Cervarix faces tough competition from Merck’s Gardasil. Launched in 2006, Gardasil has gained an early advantage as the only cervical cancer vaccine on the market. Analysts are giving Gardasil the edge. Gbola Amusa, analyst for Sanford C. Bernstein, projects $2.5 billion in peak annual sales for Gardasil and $1.5 billion for Cervarix. But GlaxoSmithKline counters that Cervarix is more powerful. The drugmaker is funding an unusual head-to-head study to try to prove that Cervarix is more potent than Gardasil. Results of the study are anticipated by January 2008.
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.